Form 4: Precigen CCO Phil Tennant Receives Equity Grant

Precigen Chief Commercial Officer Phil Tennant was granted 385,000 stock options and 115,000 restricted stock units on April 20, 2026.

Summary

• Phil Tennant, Chief Commercial Officer of Precigen, Inc., received a new equity compensation package.
• The grant includes 385,000 stock options with an exercise price of $4.11 per share.
• The grant includes 115,000 restricted stock units (RSUs), each representing a right to one share of common stock.
• Both the options and RSUs follow a four-year vesting schedule beginning May 23, 2027.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a routine administrative filing regarding executive compensation, which is neutral in terms of immediate financial impact.

Positives

• Equity grants align the interests of the Chief Commercial Officer with long-term shareholder value.
• The multi-year vesting schedule encourages executive retention.

Negatives

• The issuance of 500,000 total equity instruments results in potential future dilution for existing shareholders.

Risks

• Future share price volatility may impact the ultimate value realized by the executive from these grants.
• The company remains subject to market risks inherent in the biotechnology sector.

Future Outlook

The filing does not provide forward-looking financial guidance, focusing solely on executive compensation disclosure.

Industry Context

StockSavvy.ai notes that equity-based compensation is standard practice in the biotechnology industry to attract and retain executive talent, particularly for roles focused on commercialization.

Comparison to Industry Standards

• The four-year vesting schedule is consistent with standard corporate governance practices for executive equity awards.
• The use of both options and RSUs is a common hybrid compensation strategy used by mid-cap biotech firms to balance performance incentives and retention.

Stakeholder Impact

• Shareholders may experience minor dilution upon the eventual exercise and vesting of these equity instruments.

Next Steps

• Vesting of 25% of the options and RSUs on May 23, 2027.

Key Dates

Keywords

Precigen, PGEN, Form 4, Insider Trading, Equity Compensation, Biotech